Jong‐Youl Jin

776 total citations
41 papers, 553 citations indexed

About

Jong‐Youl Jin is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Jong‐Youl Jin has authored 41 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Jong‐Youl Jin's work include Cancer Treatment and Pharmacology (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (5 papers). Jong‐Youl Jin is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (5 papers). Jong‐Youl Jin collaborates with scholars based in South Korea, United States and United Kingdom. Jong‐Youl Jin's co-authors include E. C. Gordon‐Smith, J. Adam Tooze, Jin‐Hyoung Kang, Seok Lee, Myung‐Hoon Chun, Mun‐Yong Lee, Ki‐Seong Eom, Jong‐Wook Lee, Yoo‐Jin Kim and Chang‐Ki Min and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Jong‐Youl Jin

39 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jong‐Youl Jin South Korea	15	219	196	165	84	56	41	553
Maho Sato Japan	13	190 0.9×	141 0.7×	78 0.5×	105 1.3×	61 1.1×	49	510
Rafael Martínez Spain	11	216 1.0×	139 0.7×	252 1.5×	75 0.9×	40 0.7×	27	598
Hisaki Fujii Japan	15	176 0.8×	155 0.8×	143 0.9×	148 1.8×	34 0.6×	33	580
Masakatsu Yanagimachi Japan	14	171 0.8×	99 0.5×	155 0.9×	196 2.3×	25 0.4×	37	561
Antonio Azzarà Italy	13	122 0.6×	109 0.6×	110 0.7×	120 1.4×	20 0.4×	50	495
Roger Gooding United Kingdom	11	148 0.7×	175 0.9×	137 0.8×	192 2.3×	32 0.6×	17	586
N Tsukada Japan	15	185 0.8×	182 0.9×	159 1.0×	110 1.3×	24 0.4×	34	647
Patrick S. Gentile United States	13	105 0.5×	123 0.6×	109 0.7×	119 1.4×	93 1.7×	25	455
Heleia Roca-Ho Spain	12	80 0.4×	166 0.8×	158 1.0×	98 1.2×	18 0.3×	21	648

Countries citing papers authored by Jong‐Youl Jin

Since Specialization

Citations

This map shows the geographic impact of Jong‐Youl Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jong‐Youl Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jong‐Youl Jin more than expected).

Fields of papers citing papers by Jong‐Youl Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jong‐Youl Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jong‐Youl Jin. The network helps show where Jong‐Youl Jin may publish in the future.

Co-authorship network of co-authors of Jong‐Youl Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Jong‐Youl Jin. A scholar is included among the top collaborators of Jong‐Youl Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jong‐Youl Jin. Jong‐Youl Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Hyunho, Hyung Soon Park, Ho Jung An, et al.. (2023). A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. Journal of the Korean Gastric Cancer Association. 23(2). 315–315. 2 indexed citations

Chun, Sang Hoon, et al.. (2021). Experience of serious intestinal hemorrhage and perforation in small bowel lymphoma: a case report. SHILAP Revista de lepidopterología. 17(2). 126–130. 1 indexed citations

Choi, Jae-Ki, Sunghan Kim, Jong‐Youl Jin, et al.. (2021). Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea. Journal of Korean Medical Science. 36(31). e223–e223. 21 indexed citations

Park, Keunchil, Jin-Soo Kim, Joo-Hang Kim, et al.. (2021). An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer. 21(1). 802–802. 9 indexed citations

Yoo, Kwai Han, Jinhyun Cho, Boram Han, et al.. (2020). Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. PLoS ONE. 15(8). e0235503–e0235503. 2 indexed citations

Choi, Jung Hye, Tae Min Kim, Hyo Jung Kim, et al.. (2017). Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01. Cancer Research and Treatment. 50(2). 590–598. 7 indexed citations

Herbst, Roy S., Juan Martín-Liberal, Emiliano Calvo, et al.. (2017). Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Annals of Oncology. 28. ii32–ii33. 12 indexed citations

Kim, Soo‐Jeong, et al.. (2013). The prevalence and clinical characteristics of cancer among anemia patients treated at an outpatient clinic. Blood Research. 48(1). 46–46. 4 indexed citations

Lee, Sung Sook, Cheolwon Suh, Bong-Seog Kim, et al.. (2010). Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology. 89(9). 905–912. 16 indexed citations

10.

Lee, Jae Hoon, Dong Soon Lee, Je Jung Lee, et al.. (2010). Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. International Journal of Hematology. 92(1). 52–57. 36 indexed citations

11.

Eom, Hyeon‐Seok, Yeo‐Kyeoung Kim, Joo-Seop Chung, et al.. (2009). Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology. 89(5). 489–497. 8 indexed citations

12.

Kim, Nam Hee, et al.. (2008). Auranofin promotes retinoic acid‐ or dihydroxyvitamin D₃‐mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. British Journal of Pharmacology. 154(6). 1196–1205. 13 indexed citations

13.

Lee, Kyung‐Tae, et al.. (2005). Eugenol Induces a Reactive Oxygen Species-mediated Apoptosis in HL-60 Human Promyelocytic Leukemia Cell. The Korean Journal of Hematology. 40(2). 65–65. 1 indexed citations

14.

Kim, Hee‐Je, Woo‐Sung Min, Soo-Jeong Park, et al.. (2003). Induction Chemotherapy for Patients with Acute Myeloid Leukemia Aged over 60 Years. Blood Research. 38(4). 228–233. 1 indexed citations

15.

Han, Ji‐Youn, Eun Kyung Hong, Byung Gil Choi, et al.. (2003). Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer. Medical Oncology. 20(4). 355–362. 43 indexed citations

16.

Park, Sung‐Gyu, et al.. (2002). Arsenic Trioxide ($As_2O_3$) Induced Apoptosis in NB4 Cell lines. Blood Research. 37(3). 200–211. 1 indexed citations

17.

Jeong, Dae Chul, Chi Wha Han, Jong‐Youl Jin, et al.. (1999). Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Experimental Hematology. 27(7). 1219–1225. 3 indexed citations

18.

Jin, Jong‐Youl, et al.. (1997). Glycosylphosphatidyl‐inositol (GPI)‐linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. British Journal of Haematology. 96(3). 493–496. 17 indexed citations

19.

Jin, Jong‐Youl, et al.. (1996). Myelodysplasia following aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G‐CSF: evidence for the emergence of a separate clone. British Journal of Haematology. 94(3). 510–512. 17 indexed citations

20.

Jin, Jong‐Youl, et al.. (1995). Immune Suppression Therapy in Aplastic Anemia: Influencing Factors on Response and Survival. The Korean Journal of Internal Medicine. 10(1). 25–31. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact